Clinical Trial Update: Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing cross-neutralizing mechanisms of AS04-adjuvanted Cervarix versus aluminum hydroxyphosphate sulfate-adjuvanted Gardasil in HPV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infection with Human Papillomavirus

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)
• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Infection With Human Papillomavirus | Phase 4 | Status: COMPLETED